Reference data : LOINC code

Filter


Clear filter

Results
108,248 results found
Loinc Number Component Property System Time aspect ScaleType MethodType Relat_nms loincStatus Long Common name answerList chngType <span class='defaultText'>DefinitionDescription</span> dtLastCh exactCmspy exampleUnits exmplAnswers externalCopyrightNotice formula hl7FieldSubfieldId InpcPercentage ipccUnits loincClass loincFinal loincNum mapTo methodTyp molarMass naaccrId orderObs panelElements reference scope setRoot shortName source surveyQuestSrc surveyQuestText unitsRequired acssym relatedNames2 VersionLastChanged VersionFirstRelease ValidHL7AttachmentRequest PanelType AssociatedObservations EXTERNAL_COPYRIGHT_LINK HL7_ATTACHMENT_STRUCTURE CONSUMER_NAME EXAMPLE_UCUM_UNITS STATUS_REASON STATUS_TEXT CHANGE_REASON_PUBLIC COMMON_TEST_RANK COMMON_ORDER_RANK
100334-2 Been physically hurt with some degree of injury Find ^Patient Pt Ord &nbsp; &nbsp; ACTIVE Been physically hurt with some degree of injury &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; SURVEY.MTLHLTH &nbsp; 100334-2 &nbsp; &nbsp; &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 &nbsp; &nbsp; &nbsp; &nbsp; N &nbsp; Finding; Findings; Ordinal; Point in time; QL; Qual; Qualitative; Random; Screen; Survey; SURVEY.MTLHLTH; Ulcer 2.73 2.73 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
100335-9 Coerced sexual activity Find ^Patient Pt Ord &nbsp; &nbsp; ACTIVE Coerced sexual activity &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; SURVEY.MTLHLTH &nbsp; 100335-9 &nbsp; &nbsp; &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 &nbsp; &nbsp; &nbsp; &nbsp; N &nbsp; Activ; Actvty; Finding; Findings; Movements; Ordinal; Point in time; QL; Qual; Qualitative; Random; Screen; Survey; SURVEY.MTLHLTH 2.73 2.73 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
100336-7 Coerced touching of private body parts of self or others Find ^Patient Pt Ord &nbsp; &nbsp; ACTIVE Coerced touching of private body parts of self or others &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; SURVEY.MTLHLTH &nbsp; 100336-7 &nbsp; &nbsp; &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 &nbsp; &nbsp; &nbsp; &nbsp; N &nbsp; bod; Bodies; Finding; Findings; Ordinal; Point in time; QL; Qual; Qualitative; Random; Screen; Survey; SURVEY.MTLHLTH 2.73 2.73 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
100337-5 Coerced to undress or expose private body area Find ^Patient Pt Ord &nbsp; &nbsp; ACTIVE Coerced to undress or expose private body area &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; SURVEY.MTLHLTH &nbsp; 100337-5 &nbsp; &nbsp; &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 &nbsp; &nbsp; &nbsp; &nbsp; N &nbsp; bod; Bodies; Finding; Findings; Ordinal; Point in time; QL; Qual; Qualitative; Random; Screen; Survey; SURVEY.MTLHLTH 2.73 2.73 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
100338-3 Photographed in any degree of nudity without consent Find ^Patient Pt Ord &nbsp; &nbsp; ACTIVE Photographed in any degree of nudity without consent &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; SURVEY.MTLHLTH &nbsp; 100338-3 &nbsp; &nbsp; &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 &nbsp; &nbsp; &nbsp; &nbsp; N &nbsp; Finding; Findings; Form; Ordinal; Point in time; QL; Qual; Qualitative; Random; Screen; Survey; SURVEY.MTLHLTH 2.73 2.73 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
100339-1 Experienced attempted physical restraint Find ^Patient Pt Ord &nbsp; &nbsp; ACTIVE Experienced attempted physical restraint &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; SURVEY.MTLHLTH &nbsp; 100339-1 &nbsp; &nbsp; &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 &nbsp; &nbsp; &nbsp; &nbsp; N &nbsp; Finding; Findings; Ordinal; Point in time; QL; Qual; Qualitative; Random; Screen; Survey; SURVEY.MTLHLTH 2.73 2.73 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
10034-7 S wave amplitude.lead AVF Elpot Heart Pt Qn EKG &nbsp; ACTIVE S wave amplitude in lead AVF &nbsp; MIN DefinitionDescription &nbsp; &nbsp; mV &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; EKG.MEAS &nbsp; 10034-7 &nbsp; EKG &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 S wave Amp L-AVF &nbsp; &nbsp; &nbsp; Y &nbsp; Cardiac; Cardio; Cardiology; ECG; EKG.MEASUREMENTS; Electrical potential; Electrocardiogram; Electrocardiograph; Heart Disease; Hrt; Painter's colic; PB; Plumbism; Point in time; QNT; Quan; Quant; Quantitative; Random; S prime; S' wave Amp L-AVF; S wave Amp L-AVF; Voltage 2.48 1.0i &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; mV &nbsp; &nbsp; &nbsp; 0
100340-9 Range of motion panel - Hip Pt - &nbsp; &nbsp; ACTIVE Range of motion panel Hip &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; PANEL.SURVEY.ORTHOPEDICS &nbsp; 100340-9 &nbsp; &nbsp; &nbsp; &nbsp; Subset &nbsp; &nbsp; &nbsp; 0 &nbsp; &nbsp; &nbsp; &nbsp; N &nbsp; Lower extremity joint; Ortho; Pan; Panl; Pnl; Point in time; Random; Rnge; Survey 2.73 2.73 &nbsp; Organizer &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
100341-7 Rubella virus Ab.IgG index ACnc Ser+CSF Pt Qn &nbsp; &nbsp; ACTIVE Rubella virus IgG Ab index [Units/volume] in Serum and CSF &nbsp; ADD DefinitionDescription &nbsp; &nbsp; Index value &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; MICRO &nbsp; 100341-7 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 RUBV IgG Index Ser+CSF-aCnc &nbsp; &nbsp; &nbsp; N &nbsp; ABS; Aby; AI; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; Both serum and cerebrospinal fluid; Cerebral spinal fluid; Cerebrospinal Fl; Congenital rubella syndrome; German measles; Immune globulin G; Immunoglobulin G; Microbiology; Point in time; QNT; Quan; Quant; Quantitative; Random; RUBV; RUBV IgG Index Ser+CSF-aCnc; Serum; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; SR 2.73 2.73 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; {Index_val} &nbsp; &nbsp; &nbsp; 0
100342-5 Volatile Organic Compounds associated with SARS-CoV-2 infection PrThr Exhl gas Pt Ord GC-MS &nbsp; ACTIVE Volatile Organic Compounds associated with SARS-CoV-2 infection [Presence] in Exhaled gas by Gas chromatography-mass spectrometry &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; MICRO &nbsp; 100342-5 &nbsp; GC-MS &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 VOCs (volatiles) SARS-CoV-2 ExG Ql GC-MS &nbsp; &nbsp; &nbsp; N &nbsp; Assoc; Breath; ExG; Exhaled gas; Exhaled gas (=breath); Gas chromatography; Gases; ID; II; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; PH; Point in time; PR; Public Health; PublicHealth; Ql; Qual; Qualitative; Random; Screen; Severe Acute Respiratory Syndrome; VOCs (volatiles) SARS-CoV-2; Volatiles 2.73 2.73 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
100343-3 Influenza virus B RNA PrThr Saliva Pt Ord Probe.amp.tar &nbsp; ACTIVE Influenza virus B RNA [Presence] in Saliva (oral fluid) by NAA with probe detection &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; MICRO &nbsp; 100343-3 &nbsp; Probe.amp.tar &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 FLUBV RNA Sal Ql NAA+probe &nbsp; &nbsp; &nbsp; N &nbsp; 3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; DNA NUCLEIC ACID PROBE; DNA probe; FLUB; FLUBV; FLUV; Influ; Influenza B; Influenza B virus; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Oral fluid; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Ribonucleic acid; Sal; Screen; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification 2.73 2.73 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
100344-1 Influenza virus A RNA PrThr Saliva Pt Ord Probe.amp.tar &nbsp; ACTIVE Influenza virus A RNA [Presence] in Saliva (oral fluid) by NAA with probe detection &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; MICRO &nbsp; 100344-1 &nbsp; Probe.amp.tar &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 FLUAV RNA Sal Ql NAA+probe &nbsp; &nbsp; &nbsp; N &nbsp; 3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Avian influenza; Bird flu; DNA NUCLEIC ACID PROBE; DNA probe; FLUA; FLUAV; FLUV; Fowl plague; Influ; Influenza A; Influenza A virus; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Oral fluid; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Ribonucleic acid; Sal; Screen; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification 2.73 2.73 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
100345-8 Influenza virus A & Influenza virus B & SARS coronavirus 2 RNA panel - XXX Pt - Probe.amp.tar &nbsp; ACTIVE Influenza virus A and B and SARS-CoV-2 (COVID-19) RNA panel - Specimen by NAA with probe detection &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; PANEL.MICRO &nbsp; 100345-8 &nbsp; Probe.amp.tar &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 FLUABV+SARS-CoV-2 RNA Pnl Spec NAA+probe &nbsp; &nbsp; &nbsp; N &nbsp; 2019 Novel Coronavirus; 2019-nCoV; 3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Avian influenza; Bird flu; Corona virus; COVID19; COVID-19; DNA NUCLEIC ACID PROBE; DNA probe; FLUA; FLUABV + SARS-CoV-2; FLUABV+SARS-CoV-2 RNA Pnl; FLUAV; FLUB; FLUBV; FLUV; Fowl plague; ID; II; Infectious Disease; InfectiousDisease; Influ; Influenza A; Influenza A virus; Influenza B; Influenza B virus; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Other; Pan; PANEL.MICROBIOLOGY; Panl; PCR; PH; Pnl; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; Public Health; PublicHealth; QBR; Random; Ribonucleic acid; SARS Coronavirus 1; SARS-CoV; SARS-CoV-1; SARS-CoV-2; SARS-CoV-2 RNA Pnl; SDA; Severe Acute Respiratory Syndrome; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified; Viral Pneumonias; Wuhan coronavirus 2.73 2.73 &nbsp; Panel &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
100346-6 Clotting time.extrinsic coagulation system activated.platelets inhibited Time Bld Pt Qn Thromboelastography.rotational &nbsp; ACTIVE Clotting time.extrinsic coagulation system activated.platelets inhibited of Blood by Rotational TEG &nbsp; ADD DefinitionDescription &nbsp; &nbsp; s &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; COAG &nbsp; 100346-6 &nbsp; Thromboelastography.rotational &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 CT.extr plt inhib Bld ROTEM &nbsp; &nbsp; &nbsp; N &nbsp; Activ; Blood; Clot; Clottable; Coag; Coagulation time; CT.extr plt inhib; CT.extrinsic; Platelet; Platelt; Plt; Point in time; QNT; Quan; Quant; Quantitative; Random; Rate; ROTEM; R-time; TEG; TEM; Thrb; Thrombelastography; Thrombelastometry; Thrombocyte; Thrombocytes; Thromboelastometry; WB; Whole blood 2.73 2.73 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; s &nbsp; &nbsp; &nbsp; 0
100347-4 Clot formation.extrinsic coagulation system activated.platelets inhibited Time Bld Pt Qn Thromboelastography.rotational &nbsp; ACTIVE Clot formation.extrinsic coagulation system activated.platelets inhibited [Time] in Blood by Rotational TEG &nbsp; ADD DefinitionDescription &nbsp; &nbsp; s &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; COAG &nbsp; 100347-4 &nbsp; Thromboelastography.rotational &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 CT.extr plt inhib Bld ROTEM &nbsp; &nbsp; &nbsp; N &nbsp; Activ; Activated clotting time; Blood; CFT; CFT.extrinsic; Clot time; Coag; CT.extr plt inhib; Kinetics; k-time; Platelet; Platelt; Plt; Point in time; QNT; Quan; Quant; Quantitative; Random; ROTEM; TEG; TEM; Thrb; Thrombelastography; Thrombelastometry; Thrombocyte; Thrombocytes; Thromboelastometry; WB; Whole blood 2.73 2.73 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; s &nbsp; &nbsp; &nbsp; 0
100348-2 Model for end-stage liver disease sodium score Score ^Patient Pt Qn &nbsp; &nbsp; ACTIVE Model for end-stage liver disease sodium score &nbsp; ADD DefinitionDescription &nbsp; &nbsp; score &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; TRNSPLNT.ORGAN &nbsp; 100348-2 &nbsp; &nbsp; &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 MELDNa score &nbsp; &nbsp; &nbsp; N &nbsp; Dis; Diseases; Dz; MELDNa score; Na; Na+; Organ Transplant; Point in time; QNT; Quan; Quant; Quantitative; Random; Scale 2.73 2.73 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; {score} &nbsp; &nbsp; &nbsp; 0
100349-0 Multisection^W vasodilator IV Find Pelvis>Penis vessels Pt Doc US.doppler &nbsp; ACTIVE US.doppler Penis vessels W vasodilator IV &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; RAD &nbsp; 100349-0 &nbsp; US.doppler &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 DOP Penis ves W vasodilator IV &nbsp; &nbsp; &nbsp; N &nbsp; Document; DOP; DUPLEX; Echography; Finding; Findings; Imaging; Pelvic; Pen; Penile; Point in time; Radiology; Random; Sonogram; Sonograph; Sonography; ULS; Ultrasound; Vesl; Vessels.XXX 2.73 2.73 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
10035-4 S wave amplitude.lead AVL Elpot Heart Pt Qn EKG &nbsp; ACTIVE S wave amplitude in lead AVL &nbsp; MIN DefinitionDescription &nbsp; &nbsp; mV &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; EKG.MEAS &nbsp; 10035-4 &nbsp; EKG &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 S wave Amp L-AVL &nbsp; &nbsp; &nbsp; Y &nbsp; Cardiac; Cardio; Cardiology; ECG; EKG.MEASUREMENTS; Electrical potential; Electrocardiogram; Electrocardiograph; Heart Disease; Hrt; Painter's colic; PB; Plumbism; Point in time; QNT; Quan; Quant; Quantitative; Random; S prime; S' wave Amp L-AVL; S wave Amp L-AVL; Voltage 2.48 1.0i &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; mV &nbsp; &nbsp; &nbsp; 0
100350-8 Sesamum indicum 1 Ab.IgE ACnc Ser Pt Qn &nbsp; &nbsp; ACTIVE Sesamum indicum 1 IgE Ab [Units/volume] in Serum &nbsp; ADD DefinitionDescription &nbsp; &nbsp; kUA/l &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ALLERGY &nbsp; 100350-8 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Ses i 1 IgE Qn &nbsp; &nbsp; &nbsp; N &nbsp; ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; f010; f10; i; Immune globulin E; Immunoglobulin E; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; Ses i 1; Ses I 1 Ab.IgE; Sesame Seed; Sesamum orientale; SR 2.73 2.73 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; kU/L &nbsp; &nbsp; &nbsp; 0
100351-6 Pioglitazone PrThr Ser/Plas Pt Ord &nbsp; &nbsp; ACTIVE Pioglitazone [Presence] in Serum or Plasma &nbsp; ADD DefinitionDescription &nbsp; &nbsp; Qualitative &nbsp; &nbsp; 20 ng/mL Cutoff &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 100351-6 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Pioglitazone SerPl Ql &nbsp; &nbsp; &nbsp; N &nbsp; Actos; DRUG/TOXICOLOGY; Drugs; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR 2.73 2.73 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ng/mL &nbsp; &nbsp; &nbsp; 0
100352-4 Rosiglitazone PrThr Ser/Plas Pt Ord &nbsp; &nbsp; ACTIVE Rosiglitazone [Presence] in Serum or Plasma &nbsp; ADD DefinitionDescription &nbsp; &nbsp; Qualitative &nbsp; &nbsp; 20 ng/mL Cutoff &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 100352-4 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Rosiglitazone SerPl Ql &nbsp; &nbsp; &nbsp; N &nbsp; Avandia; DRUG/TOXICOLOGY; Drugs; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR 2.73 2.73 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ng/mL &nbsp; &nbsp; &nbsp; 0
100353-2 Norwalk Community Health Center Screening Tool - ^Patient Pt - NCHC &nbsp; ACTIVE Norwalk Community Health Center Screening Tool [NCHC] &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; PANEL.SURVEY.SDOH &nbsp; 100353-2 &nbsp; NCHC &nbsp; &nbsp; Order &nbsp; &nbsp; &nbsp; 0 &nbsp; &nbsp; &nbsp; &nbsp; N &nbsp; Activity; Asympt; Asymptomatic; Exercise; Pan; Panel; Panl; Pnl; Point in time; Random; Scn; SDOH; Survey 2.73 2.73 &nbsp; Panel &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
100354-0 Frequency of participating in multi-modal communication without assistance Find ^Patient Pt Ord &nbsp; &nbsp; ACTIVE Frequency of participating in multi-modal communication without assistance &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; SURVEY.SLP &nbsp; 100354-0 &nbsp; &nbsp; &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 &nbsp; &nbsp; &nbsp; &nbsp; N &nbsp; Finding; Findings; Ordinal; Point in time; QL; Qual; Qualitative; Random; Screen; SLP; Survey; SURVEY.SLP 2.73 2.73 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
100355-7 Frequency of participating in spoken language expression communication without assistance Find ^Patient Pt Ord &nbsp; &nbsp; ACTIVE Frequency of participating in spoken language expression communication without assistance &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; SURVEY.SLP &nbsp; 100355-7 &nbsp; &nbsp; &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 &nbsp; &nbsp; &nbsp; &nbsp; N &nbsp; Finding; Findings; Ordinal; Point in time; QL; Qual; Qualitative; Random; Screen; SLP; Survey; SURVEY.SLP 2.73 2.73 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
100356-5 Chlamydia trachomatis & Neisseria gonorrhoeae & Trichomonas vaginalis DNA Prid XXX Pt Nom Probe.amp.tar &nbsp; ACTIVE Chlamydia trachomatis and Neisseria gonorrhoeae and Trichomonas vaginalis DNA [Identifier] in Specimen by NAA with probe detection &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; MICRO &nbsp; 100356-5 &nbsp; Probe.amp.tar &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 CT + NG + TV DNA Spec NAA+probe &nbsp; &nbsp; &nbsp; N &nbsp; 3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; C trac; C trach; C trach+GC; C tracho; C trachomatis; Chlam; Chlam trac; Chlamid; CT; CT + NG + TV; CT + NG + TV DNA; CT/GC; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; GC; Gono; Gonorrhea; Identity or presence; LAT; LCR; LGV; Ligase chain reaction; Ligation-activated transcription; Lymphogranuloma venereum; Microbiology; Misc; Miscellaneous; N gonorrhoea; N gonorrhoeae; NAA+probe; NAAT; NASBA; Nominal; Nucleic acid sequence based analysis; Other; PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; Random; SDA; Spec; Strand Displacement Amplification; T vaginalis; TMA; To be specified in another part of the message; Trachoma; Transcription mediated amplification; Tric; Trich; Trichimoniasis; Trichomonad; Trichomonads; Trichomoniasis; Unspecified 2.73 2.73 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
108,248 results found